CoChat

Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer

Open access
Wolpin, Brian M., Ng, Kimmie, Zhu, Andrew X., Abrams, Thomas, Enzinger, Peter C., McCleary, Nadine J., Schrag, Deborah, Kwak, Eunice L., Allen, Jill N., Bhargava, Pankaj, Chan, Jennifer A., Goessling, Wolfram, Blaszkowsky, Lawrence S., Supko, Jeffrey G., Elliot, Meaghan, Sato, Kaori, Regan, Eileen, Meyerhardt, Jeffrey A., Fuchs, Charles S. · 2013 · The Oncologist
Cited by 43

The DOI matches its Crossref record.

Abstract

Background.: Treatments that target the vascular endothelial growth factor (VEGF) pathway have efficacy in colorectal cancer. We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor). Methods.: The phase Ib study followed a 3 + 3 dose-escalation design with three dose levels. The primary objective in the follow-on phase II study was improvement in 2-month progression-free survival (PFS) from 30% (historical benchmark) to 50% in patients with refractory, metastatic colorectal cancer. Results.: Dose-limiting toxicities in the phase Ib study were grade 3 fatigue and dehydration. Oral tivozanib (1 mg daily for 3 of 4 weeks) and oral everolimus (10 mg daily continuously) were advanced to a 40-patient phase II study. The most common grade 3–4 adverse events were thrombocytopenia and hypophosphatemia. The 2-month PFS rate was 50%, with 20 of 40 patients having stable disease (SD). Seven (18%) patients were treated for ≥6 months. Median PFS and overall survival (OS) times were 3.0 months (95% confidence interval [CI]: 1.9–3.6 months) and 5.6 months (95% CI: 4.4–10.6 months), respectively. Patients who developed grade 1+ hypertension had increased SD rates (65.2% vs. 29.4%) and longer OS times (10.6 vs. 3.7 months). Conclusions.: The oral combination of tivozanib and everolimus was well tolerated, with stable disease achieved in 50% of patients with refractory, metastatic colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1634/theoncologist.2012-0378

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 43

Metadata

Authors
Wolpin, B. M., Ng, K., Zhu, A. X., Abrams, T., Enzinger, P. C., McCleary, N. J., Schrag, D., Kwak, E. L., Allen, J. N., Bhargava, P., Chan, J. A., Goessling, W., Blaszkowsky, L. S., Supko, J. G., Elliot, M., Sato, K., Regan, E., Meyerhardt, J. A., & Fuchs, C. S.
Venue
The Oncologist
Published
2013-04-01
Volume
18
Issue
4
Pages
377-378
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W2034209904
Cited by
43
References
0
FWCI
2.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.2012-0378
The paper
Wolpin, B. M., Ng, K., Zhu, A. X., Abrams, T., Enzinger, P. C., McCleary, N. J., Schrag, D., Kwak, E. L., Allen, J. N., Bhargava, P., Chan, J. A., Goessling, W., Blaszkowsky, L. S., Supko, J. G., Elliot, M., Sato, K., Regan, E., Meyerhardt, J. A., & Fuchs, C. S. (2013). Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.2012-0378

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.